Articles published by Apellis Pharmaceuticals, Inc.
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2024
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
February 26, 2024
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
January 08, 2024
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2024
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
December 14, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
December 11, 2023
Via GlobeNewswire
Tickers
APLS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.